Overview
OPKO Q3 2025 total revenue declines to $151.7 mln from $173.6 mln in 2024
Operating income rises to $48.1 mln in Q3 2025, aided by asset sale gain
Net income for Q3 2025 stable at $21.6 mln, EPS remains $0.03
Outlook
Company did not provide specific financial guidance for future periods in its press release
Result Drivers
REGENERON COLLABORATION - OPKO entered a research collaboration with Regeneron Pharmaceuticals, potentially exceeding $1 bln in value, which could drive future revenue through milestone payments and royalties
ASSET SALE TO LABCORP - Sale of BioReference oncology assets to Labcorp for $225 mln contributed to operating income gain
COST REDUCTION - Lower clinical test volumes from asset sale and cost-reduction initiatives at BioReference reduced expenses
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue from Services | $95.20 mln | ||
Q3 Net Income | $21.60 mln | ||
Q3 Basic EPS | $0.03 | ||
Q3 Operating Income | $48.10 mln | ||
Q3 Pretax Profit | $41.40 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for OPKO Health Inc is $3.00, about 52% above its October 28 closing price of $1.44
Press Release: ID:nGNX67ggkq
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)